HomeCompareDWUS vs PFE

DWUS vs PFE: Dividend Comparison 2026

DWUS yields 0.03% · PFE yields 6.13%● Live data

vsPost on X →
After 10 years · $10,000 invested · DRIP enabled
🏆 PFE wins by $29.8K in total portfolio value· pulled ahead in Year 8
10 years
DWUS
DWUS
● Live price
0.03%
Share price
$50.27
Annual div
$0.02
5Y div CAGR
0%
Payout ratio
50%
After 10 yrs · $10,000 · DRIP
Portfolio value
$19.7K
Annual income
$3.22
Full DWUS calculator →
PFE
Pfizer Inc.
● Live price
6.13%
Share price
$28.08
Annual div
$1.72
5Y div CAGR
13.2%
Payout ratio
50%
After 10 yrs · $10,000 · DRIP
Portfolio value
$49.6K
Annual income
$26,258.71
Full PFE calculator →

Portfolio growth — DWUS vs PFE

📍 PFE pulled ahead of the other in Year 8

Annual dividend income

🛡️

Recession Test — Did They Cut Dividends?

How each stock treated shareholders during the 3 biggest crises of the last 20 years

Crisis PeriodDWUSPFE
2008–2009
GFC
— No data— No data
2020 Q1–Q2
COVID
— No data— No data
2022 Q4
Rate Hike
— No data— No data
Based on dividend payment history. "Increased" = dividend grew during crisis. "Maintained" = held within 3%. "Cut" = reduced by more than 3%.
📅

Dividend Calendar Overlap

Combined, DWUS + PFE cover 0 of 12 monthsgood coverage

Jan
Feb
Mar
Apr
May
Jun
Jul
Aug
Sep
Oct
Nov
Dec
DWUS pays
PFE pays
Both pay
Neither
💰

Tax Bracket Optimizer

Which stock is actually better after tax? Adjust your rate to find out.

DWUS
Annual income on $10K today (after 15% tax)
$2.73/yr
After 10yr DRIP, annual income (after tax)
$2.74/yr
PFE
Annual income on $10K today (after 15% tax)
$520.66/yr
After 10yr DRIP, annual income (after tax)
$22,319.90/yr
At 15% tax rate, PFE beats the other by $22,317.17/year in after-tax income after 10 years on $10,000
⚖️

Lazy Portfolio Split Optimizer

What's the optimal mix of DWUS + PFE for your $10,000?

DWUS: 50%PFE: 50%
100% PFE50/50100% DWUS
Portfolio after 10yr
$34.6K
Annual income
$13,130.97/yr
Blended yield
37.91%
📊

Analyst Conviction Gap

Where Wall Street is most bullish on PFE right now

DWUS
No analyst data
PFE
Analyst Ratings
16
Buy
22
Hold
1
Sell
Consensus: Hold
Price Target
$27.50
-2.1% upside vs current
Range: $24.00 — $35.00
Altman Z
2.0
Piotroski
5/9
Analyst ratings via FMP. Altman Z-Score: >3.0 safe, 1.81–3.0 grey zone, <1.81 distress. Piotroski: 7–9 strong, 0–3 weak.
🏛️

Copy Congress — What Are Politicians Buying?

Senate & House STOCK Act disclosures (last 90 days)

DWUS buys
0
PFE buys
8
PoliticianChamberTickerTypeAmountDate
Gilbert Cisneros🏢 House$PFE▲ Buy$1,001 - $15,0002026-02-10
Susan M. Collins🏛 Senate$PFE▲ Buy$15,001 - $50,0002026-02-03
James French Hill🏢 House$PFE▼ Sell$100,001 - $250,0002025-12-31
Gilbert Cisneros🏢 House$PFE▼ Sell$1,001 - $15,0002025-12-19
Ro Khanna🏢 House$PFE▼ Sell$1,001 - $15,0002025-09-15
Ro Khanna🏢 House$PFE▼ Sell$1,001 - $15,0002025-09-05
Gilbert Cisneros🏢 House$PFE▼ Sell$1,001 - $15,0002025-08-05
Lisa McClain🏢 House$PFE▲ Buy$1,001 - $15,0002025-07-16
Ron Wyden🏛 Senate$PFE▼ Sell$1,001 - $15,0002025-06-03
Ron Wyden🏛 Senate$PFE▼ Sell$1,001 - $15,0002025-06-03
STOCK Act mandates disclosure within 45 days of transaction. Data via FMP.Full tracker →
MetricDWUSPFE
Forward yield0.03%6.13%
Annual dividend / share$0.02$1.72
Payout ratio50%50%
1-year div growth0%0%
5-year div CAGR0%13.2%
Portfolio after 10y$19.7K$49.6K
Annual income after 10y$3.22$26,258.71
Total dividends collected$32.00$58.3K
Payment frequencyquarterlyquarterly
SectorStockHealthcare

Year-by-year: DWUS vs PFE ($10,000, DRIP)

YearDWUS PortfolioDWUS Income/yrPFE PortfolioPFE Income/yrGap
1$10,703$3.21$9,153$693.39+$1.6KDWUS
2$11,456$3.21$8,593$849.25+$2.9KDWUS
3$12,261$3.21$8,336$1,066.78+$3.9KDWUS
4$13,122$3.21$8,437$1,384.80+$4.7KDWUS
5$14,044$3.21$9,013$1,875.40+$5.0KDWUS
6$15,030$3.21$10,306$2,680.72+$4.7KDWUS
7$16,086$3.21$12,820$4,101.38+$3.3KDWUS
8← crossover$17,215$3.21$17,673$6,826.70$458.00PFE
9$18,423$3.22$27,543$12,591.86$9.1KPFE
10$19,716$3.22$49,560$26,258.71$29.8KPFE

DWUS vs PFE: Complete Analysis 2026

DWUSStock

Alpha-Seeking Complement to Broad Based Exposure – Broad based indexes, by their nature, have the good and the bad, the strong and the weak. DWUS seeks to add alpha using Dorsey Wright’s historically successful trend following process and investment modeling that looks to identify the strongest U.S. large cap equity investments from the weaker performers. Active Management Advantage – Many ETFs passively invest owning all the stocks represented in their benchmark index, including those with less than attractive investing attributes. DWUS’s investment process regularly and systematically screens its investment universe for domestic large cap equity asset classes to include or remove from its highly tactical, active portfolio. U.S. Core Equity Rotation – Investment styles rotate in and out of season. Owning or even avoiding certain large cap investing styles – equal weight, cap-weight, growth, value, low volatility, momentum– is an important determinant of domestic core equity success. By investing in the highest-ranked funds in its investment universe , DWUS seeks to capture the growth of those large cap U.S. equity styles demonstrating the strongest relative strength while avoiding the weakest. Systematic Defense – Because we believe avoiding severe losses helps to preserve capital and can contribute to good performance over time, DWUS uses a rules-based approach to tactically add cash or short-term fixed income exposure to the portfolio when a defense indicator is triggered. The temporary defensive position is to try to shield the portfolio from certain catastrophic market types.

Full DWUS Calculator →

PFEHealthcare

Pfizer Inc. discovers, develops, manufactures, markets, distributes, and sells biopharmaceutical products worldwide. It offers medicines and vaccines in various therapeutic areas, including cardiovascular metabolic and women's health under the Premarin family and Eliquis brands; biologics, small molecules, immunotherapies, and biosimilars under the Ibrance, Xtandi, Sutent, Inlyta, Retacrit, Lorbrena, and Braftovi brands; and sterile injectable and anti-infective medicines, and oral COVID-19 treatment under the Sulperazon, Medrol, Zavicefta, Zithromax, Vfend, Panzyga, and Paxlovid brands. The company also provides medicines and vaccines in various therapeutic areas, such as pneumococcal disease, meningococcal disease, tick-borne encephalitis, and COVID-19 under the Comirnaty/BNT162b2, Nimenrix, FSME/IMMUN-TicoVac, Trumenba, and the Prevnar family brands; biosimilars for chronic immune and inflammatory diseases under the Xeljanz, Enbrel, Inflectra, Eucrisa/Staquis, and Cibinqo brands; and amyloidosis, hemophilia, and endocrine diseases under the Vyndaqel/Vyndamax, BeneFIX, and Genotropin brands. In addition, the company is involved in the contract manufacturing business. It serves wholesalers, retailers, hospitals, clinics, government agencies, pharmacies, and individual provider offices, as well as disease control and prevention centers. The company has collaboration agreements with Bristol-Myers Squibb Company; Astellas Pharma US, Inc.; Myovant Sciences Ltd.; Akcea Therapeutics, Inc; Merck KGaA; Valneva SE; BioNTech SE; and Arvinas, Inc. Pfizer Inc. was founded in 1849 and is headquartered in New York, New York.

Full PFE Calculator →
📬

Get this DWUS vs PFE comparison by email

Save your analysis + weekly dividend insights. Free forever.

More comparisons

DWUS vs SCHDDWUS vs JEPIDWUS vs ODWUS vs KODWUS vs MAINDWUS vs JNJDWUS vs MRKDWUS vs ABBV

⚠️ Educational purposes only. Not financial advice. Congressional trades sourced from SEC STOCK Act filings via FMP. Past performance does not guarantee future results.